Apollo Endosurgery, Inc. (APEN) Stock

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.

Apollo Endosurgery, Inc. is headquartered in US.

Apollo Endosurgery, Inc. (APEN) stock trades at $10.00 with a market capitalization of $579.72M. The stock is valued at a price-to-earnings (P/E) ratio of -10.20, price-to-book of 12.47, price-to-sales of 7.54. Over the past 52 weeks the stock has ranged between $3.49 and $10.30, and currently trades 2.9% below its 52-week high.

On profitability, Apollo Endosurgery, Inc. generates a return on equity (ROE) of -84.92%, return on capital employed of -39.35%, an operating margin of -36.20%, a net profit margin of -51.84%.

Official website: www.endura.com